Project Grant R01CA315846
Award Date 8/10/26
Completion Date 7/31/31
Dollars Obligated $582K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $687,594 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and characterize preclinical models of small cell lung cancer brain metastasis and evaluate therapeutic response. The recipient is conducting research to establish spontaneous brain metastasis models in patient-derived xenografts (PDXs) of small cell lung cancer. The work addresses a critical gap in SCLC research:...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas Health Science Center at Houston $635,948 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate phospholipase D1 (PLD1) and transferrin receptor 1 (TFR1) as therapeutic targets in chromosome 3q-amplified non-small cell lung cancer. The project will define the mechanisms by which PLD1 promotes NSCLC progression and tumor microenvironment...
- The National Cancer Institute awarded MD Anderson Cancer Center $669,540 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the roles of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy. The research investigates CD24 signaling in KRAS-mutant lung adenocarcinomas (KM-LUADs), which account for approximately 30 percent of lung adenocarcinomas in lifetime smokers. Preliminary findings indicate CD24 elevation...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Institutes of Health National Cancer Institute awarded the University of Virginia $730,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify N6-methyladenosine (M6A) marks and genes influencing lung cancer risk. The award funds a five-year project (August 1, 2026 through July 31, 2031) combining genetic epidemiology, multi-omics analysis, and in vitro studies to characterize M6A's role in lung tumorigenesis. The work includes conducting an...
- The National Institutes of Health National Cancer Institute awarded The University of Texas Southwestern Medical Center $426,828 on August 6, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate jumonji lysine demethylase enzymes as therapeutic targets in small cell lung cancer. The research evaluates jumonji demethylases as key contributors to SCLC development and acquired resistance to therapy. The work employs genetically engineered mouse models representing both...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $192,224 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on secreted peptides as biomarkers and effectors of neuroendocrine transformation in lung cancer. The funded work investigates pulmonary neuroendocrine cell (PNEC) biology and the histologic transformation of lung adenocarcinoma to small cell lung cancer. The research employs a genetically engineered...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $501,803 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decode the stromal niches of antigen-presenting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. The research aims to elucidate interactions between antigen-presenting cancer-associated fibroblasts (APCAFs) and other cell types within specialized stromal niches in pancreatic tumors. The work will examine...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $388,546 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how chromosome 3q amplification drives non-small cell lung cancer progression through Golgi-dependent secretory pathways and to develop manganese-based targeted therapy for this genetically defined cancer subset. The award funds research into the molecular mechanisms by which two chromosome 3q-encoded...